foslevodopa foscarbidopa


( Last Updated : November 23, 2022)
Generic Name:
foslevodopa foscarbidopa
Project Status:
Received
Therapeutic Area:
Parkinson’s disease
Manufacturer:
AbbVie Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0768-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of motor fluctuations in patients with advanced Parkinson’s disease who are not adequately controlled on oral therapies
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of motor fluctuations in patients with advanced Parkinson’s disease.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 18, 2022
Call for patient/clinician input closedDecember 08, 2022
Submission receivedNovember 23, 2022
Submission accepted